NCT05998395View on ClinicalTrials.gov

JAK/STAT Inhibition in CNS Kohlmeier-Degos Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

September 28, 2023

Primary Completion Date

February 28, 2025

Study Completion Date

February 28, 2025

Conditions
Kohlmeier Degos Disease With Neurologic Involvement
Interventions
DRUG

Ruxolitinib

Ruxolitinib at 5 mg twice a day (BID) for 1 week and then at 10 mg BID for 13-73 weeks and 1 week of 5 mg BID before stopping ruxolitinib.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH